KNSA Kiniksa Pharmaceuticals International, plc — earnings, filings & institutional moves

Price chart

Daily historical data with per-account defaults

Latest close

$62.58

Period return

+20.75 (+49.61%)

Volume

520.5K

2026-07-20O $63.6 H $65 L $62.13 C $62.58MA5 $62.26MA20 $62.08MA60 $55.74MA120 $50.68

6M · 124 barsYahoo Finance · USD2026-01-21 → 2026-07-20

Recent event timeline

Filings, earnings, research, and institutional changes — newest first

View all →

2026. 07. 28.Highin 7 days
다음 실적 발표 예정
예정된 실적 발표입니다. 일정과 시장 기대치를 확인하세요.
2026. 04. 30.LowBUY3 months ago
Canaccord Genuity: Buy
US analyst rating / recommendation change.
2026. 04. 30.LowBUY3 months ago
Citigroup: Buy
US analyst rating / recommendation change.
2026. 04. 30.LowBUY3 months ago
Wedbush: Outperform
US analyst rating / recommendation change.
2026. 04. 30.LowBUY3 months ago
Wells Fargo: Overweight
US analyst rating / recommendation change.
2026. 04. 29.LowBUY3 months ago
Jefferies: Buy
US analyst rating / recommendation change.
2026. 04. 16.LowBUY3 months ago
Wedbush: Outperform
US analyst rating / recommendation change.
2026. 02. 25.LowBUY5 months ago
Wells Fargo: Overweight
US analyst rating / recommendation change.
2026. 02. 25.LowBUY5 months ago
Wedbush: Outperform
US analyst rating / recommendation change.
2026. 02. 19.MediumBUY5 months ago
Canaccord Genuity: Buy
US analyst rating / recommendation change.

Recent earnings

Consensus vs. actual, and revenue trend

Earnings tab →

Research actions

Consensus PT $63.5 · 8 analysts

Research tab →

AI Brief (Premium)

Automated summary from public sources · not investment advice

Brief tab →

No AI brief generated yet. You can create one from the Brief tab.

Top institutions (13F)

Ranked by position value

Institutions tab →

Company info

Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage. The company was formerly known as Kiniksa Pharmaceuticals, Ltd. and changed its name to Kiniksa Pharmaceuticals International, plc in June 2024. Kiniksa Pharmaceuticals International, plc was incorporated in 2015 and is based in London, the United Kingdom.

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
HQ: London, United Kingdom
Fiscal year end: —
Employees: 366
IPO date: —

Quarter	Date	Time	EPS est.	EPS actual	Surprise	Rev. est.	Rev. actual	Status
—	2026. 07. 28.	After market close (AMC)	$0.3	—	—	$226.53M	—	Scheduled
FY2026 Q1	2025. 03. 31.	Time TBD	—	$0.11	—	—	$137.79M	Reported
FY2025 Q3	2024. 09. 30.	Time TBD	—	$-0.48	—	—	$300.7M	Reported
FY2025 Q2	2024. 06. 30.	Time TBD	—	$-0.31	—	—	$188.49M	Reported

Kiniksa Pharmaceuticals International, plc

Price chart

Recent event timeline

Recent earnings

Research actions

Top news

Key stats

Date	Firm	Analyst	Action	Rating change	Price target	Report
2026. 04. 30.	Canaccord Genuity	—	Maintain	Buy → Buy	—	Canaccord Genuity: Buy
2026. 04. 30.	Citigroup	—	Maintain	Buy → Buy	—	Citigroup: Buy
2026. 04. 30.	Wedbush	—	Maintain	Outperform → Outperform	—	Wedbush: Outperform
2026. 04. 30.	Wells Fargo	—	Maintain	Overweight → Overweight	—	Wells Fargo: Overweight
2026. 04. 29.	Jefferies	—	Maintain	Buy → Buy	—	Jefferies: Buy
2026. 04. 16.	Wedbush	—	Maintain	Outperform → Outperform	—	Wedbush: Outperform